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ABSTRACT
RUNX family proteins are expressed from alternate
promoters, giving rise to different N-terminal forms,
but the functional difference of these isoforms is not
understood. Here, we show that growth of a human
B lymphoblastoid cell line infected with Epstein–
Barr virus is inhibited by RUNX1c but not by
RUNX1b. This gives a novel functional assay for
the unique N-terminus of RUNX1c, and amino
acids of RUNX1c required for the effect have been
identified. Primary resting B cells contain RUNX1c,
consistent with the growth inhibitory effect in
B cells. The oncogene TEL–RUNX1 lacks the
N-terminus of RUNX1c because of the TEL fusion
and does not inhibit B cell growth. Mouse Runx1c
lacks some of the sequences required for human
RUNX1c to inhibit B cell growth, indicating that
this aspect of human B cell growth control may
differ in mice. Remarkably, a cell-penetrating
peptide containing the N-terminal sequence of
RUNX1c specifically antagonizes the growth inhibi-
tory effect in B lymphoblastoid cells and might be
used to modulate the function of human RUNX1c.
INTRODUCTION
The mammalian RUNX gene family consists of the
RUNX1, RUNX2 and RUNX3 genes. They express
distinct runt family transcription factors that differentially
regulate lineage-speciﬁc gene expression in several devel-
opmental pathways (1–3). All three transcription factors
have strong protein sequence similarity, particularly in the
DNA-binding ‘runt homology domain’ (RHD), and are
thought to bind similar consensus DNA sequences.
Despite similar DNA binding activities, there are few
functional overlaps in vivo as demonstrated by the highly
distinct knockout phenotypes in mice (3). Part of the ex-
planation for this lack of functional redundancy is a
distinct spatiotemporal control of expression of each
Runx family member that makes co-expression of two
Runx genes in the same cell type unusual (4,5).
However, there are likely also to be functional differences
between the different RUNX proteins; this article
identiﬁes a novel growth regulation function of RUNX1
that requires the unique N-terminus of RUNX1c.
RUNX1 is the best characterized RUNX family
member because of its key role in haematopoietic devel-
opment. In mice, it is expressed ﬁrst in the embryo during
the early development of haematopoietic stem cells in the
dorsal aorta where it is required for the maturation of
these cells (6,7). Consistent with this, knockout mice
exhibit a complete absence of deﬁnitive haematopoiesis
in the liver and die at E12.5 (8). RUNX1 additionally
plays key roles in adult haematopoiesis (9,10). It is
also frequently translocated in lymphoid cancers where
it becomes fused to TEL (TEL–RUNX1) in
malignancies of B-cells and ETO (RUNX1–ETO) in
myeloid leukaemia (1).
Like all RUNX gene family members, the transcription
of RUNX1 occurs from two distinct promoters
(Figure 1B): the P1 (distal) and the P2 (proximal)
promoter (11). Expression from these promoters is
tightly controlled during haematopoietic development (3)
and is functionally non-redundant (12). Expression from
P1 or P2 gives rise to distinct isoforms of RUNX1 derived
from the ﬁrst promoter-speciﬁc exons and differential
splicing of the sequences encoding the N-terminal parts
of the proteins. The major isoform of RUNX1 expressed
from the P1 promoter is RUNX1c, whereas the major
isoform expressed from the P2 promoter is RUNX1b.
These proteins differ by the presence of 32 unique
N-terminal amino acids in RUNX1c (Figure 1A) and 5
unique N-terminal amino acids in RUNX1b; the remain-
ing 448 amino acids are identical in the two proteins. In
RUNX3, the equivalent forms are called RUNX3p46 (P1)
and RUNX3p44 (P2). Although some differences in bio-
chemical activity have been observed for the two RUNX1
isoforms (13,14), a detailed analysis of how they differ
functionally has not yet been possible because of lack of
a model system where a clear differential activity can be
demonstrated.
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Figure 1. RUNX1c but not RUNX1b represses B cell proliferation. (A) Clustal W alignment of RUNX1c from different species. (B) Diagram of
RUNX1 gene with an alignment of the genomic DNA sequence spanning exon 2 of human RUNX1c and the orthologous mouse RUNX1 gene
sequence. Nucleotides shown are human hg19 chr21:36265209–36265270, mouse mm10 chr16:92701388–92701446. The position of exon 2 is marked
above the amino acids ECILGMNPSRDVH that are encoded by exon 2. The essential AG of the PynAG splice acceptor consensus before the start
of the exon is changed to GG in the mouse sequence. (C) IB4 LCLs were electroporated with pCEP4 constructs expressing indicated chimera and
wild-type RUNX products, then selected with hygromycin and counted after 2 weeks selection. The results presented show the average cell number
from 4–6 determinations with standard deviation shown by error bars. (D) Diagram aligning the canonical RUNX structure with chimera R1–R3,
constructed by fusion of RUNX1c amino acids 1–172 to amino acids 150–415 of RUNX3p44. TA indicates transactivation domain, and RHD is runt
homology domain (DNA binding). (E) Expression of RUNX3 constructs with chimera R1–R3 in HEK293T cells was detected by immunoblotting
lysates and probing using an anti-RUNX3 antibody with a b-actin loading control. (F) RUNX1c and RUNX1b were shown to be expressed in IB4
cells by immunoblotting lysates, and both demonstrated nuclear localization in IB4 and HEK293T cells by confocal microscopy. Data are repre-
sentative of four separate experiments.
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We previously reported that the Epstein-Barr virus
(EBV) transcription factor EBNA2 induces RUNX3p44
on infection of resting B cells and is essential for prolifer-
ation of these cells (15,16). Resting B cells express high
levels of RUNX1c, but its expression abruptly ceases after
B cell activation or EBV infection. We demonstrated a key
role for RUNX3p44 in this process by repressing RUNX1c
expression through direct binding of RUNX3p44 to two
RUNX consensus binding sites near the Runx1 P1 tran-
scription start. The removal of RUNX1c by this mechan-
ism during B cell activation was shown to be essential for
proliferation of the B cells because artiﬁcial expression of
RUNX1c in proliferating lymphoblastoid cell lines (LCLs)
blocked cell growth (17).
We have now found that this ability of RUNX1c to pre-
vent B cell growth speciﬁcally requires the N-terminus of
RUNX1c, as RUNX1b does not cause the growth inhib-
ition. This creates a convenient assay to deﬁne a novel
functional domain within the N-terminus of RUNX1c,
and we have identiﬁed the amino acids in the N-terminal
domain that are required. Remarkably, a synthetic peptide
corresponding to the N-terminal sequence prevents the
ability of RUNX1c to inhibit B cell growth; this peptide




Unless stated, all RUNX3 and RUNX1 constructs were
constructed in the pCEP4 or pMEP4 vectors (Invitrogen)
inserting between the KpnI and NotI sites. Chimera R1–
R3 consists of residues 1–172 of RUNX1c followed by
residues 150–415 RUNX3p44. All other vectors were
reported previously (17). pCEP4–RUNX1b was con-
structed by polymerase chain reaction (PCR) ampliﬁca-
tion of RUNX1c from residue 33 using a forward
primer with a 50 overhanging sequence encoding the
RUNX1b N-terminus (MRIP). RUNX1c truncation
mutants were constructed by amplifying RUNX1c from
different regions along the N-terminus. Site-directed
mutants of the RUNX1c N-terminus and the DNA-
binding mutant (DBM) were generated using overlapping
primer sets introducing the relevant mutation with the
Quickchange mutagenesis kit (Stratagene). The
pMEP4-TAP-tag (TT) root vector was constructed by
ligating the TAP-tag sequence between the NotI and
BamHI sites of pMEP4 for fusion to the C-terminus of
RUNX1 sequences. The RUNX1cE20–H32 splice
variant was made by PCR amplifying RUNX1c starting
at residue 33 (DAST) using a forward primer with an
overhang containing the upstream sequence of the
RUNX1c N-terminus (MASDSIFESFPSYPQCFMR).
RUNX1c VWRPY was generated by PCR amplifying
RUNX1c coding sequence and introducing a stop codon
before the VWRPY coding sequence. RUNX1 fusion
cDNAs TEL–RUNX1 and RUNX1–ETO (a kind gift
from Tony Ford) were sub-cloned into pCEP4. CBF-




ATC and inserted into the HindIII and NotI sites of
pBKCMV (Agilent Technologies). CBF-b was also
sub-cloned into pET28A (Novagen) between the HindIII
and NotI sites for recombinant expression with a Poly-His
tag.
Cell lines
DG75 (18) is an EBV-negative BL cell line. IB4 is an
EBV-immortalized LCL (19). Cell lines were maintained
in RPMI 1640 (Gibco-BRL) supplemented with 10% (v/v)
heat-inactivated fetal calf serum, penicillin and strepto-
mycin. Inducible cell lines were maintained in the same
medium with 300 mg/ml of hygromycin. Human embry-
onic kidney (HEK) 293T cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% (v/v) fetal calf serum and antibiotics. The 293T cells
were transfected using Genejuice (Merck).
Immunoblotting and antibodies
Radioimmunoprecipitation assay (RIPA) lysates were
prepared, and immunoblotting was performed as
described (17). Where indicated, samples were normalized
by cell counting then lysed and sonicated. For immuno-
blotting, membranes were probed with: 1/200 dilution of
rabbit polyclonal antibodies (Oncogene research
products), anti-AML-1 (RUNX1) RHD (Ab-2), anti-
AML-2 (RUNX3) (Ab-1), 1/1000 of RUNX1 monoclonal
antibody (M-201; Santa Cruz), 1/5000 of GAPDH
(AM300; Ambion), 1/500 of CBF-b (PA1-317; Pierce) or
a 1/5000 dilution of mouse monoclonal anti-b-actin
(AC-15; Sigma). The monoclonal anti-BZLF1 antibody
has been described previously (20). Secondary antibodies
were horseradish peroxidase-conjugated goat anti-rabbit
immunoglobulin (Sigma) or horseradish peroxidase-
conjugated sheep anti-mouse immunoglobulin (Sigma).
Bound immunocomplexes were detected by enhanced
chemiluminescence (GE Healthcare).
RNA extraction and reverse transcription–PCR
Total cell RNA was extracted with TRIzol (Invitrogen).
Cytoplasmic RNA was extracted with the RNeasy kit and
treated on the column with RNase-free DNase (Qiagen).
cDNA was prepared with a Protoscript Erst-strand cDNA
synthesis kit (New England Biolabs) using oligo(dT). To
detect the expression of BLK and GAPDH, a GoTaq
PCR system (Promega) was used with the following
primers: BLK (TTCTTTAGATCACAGGGTCG and A




10 cm dishes of 293HEK cells transfected with RUNX1
and CBF-b plasmids or induced pMEP4–RUNX1TT
cell lines were lysed with RIPA buffer. Lysates,
normalized using a Bradford DC protein assay
(Bio-Rad), were incubated for 4 h at 4C with
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anti-Flag-beads (Sigma), washed three times with RIPA
and the beads were boiled in sample buffer for analysis by
immunoblotting. Recombinant CBF-b–His was produced
in BL21 Escherichia coli and puriﬁed using Nickel-NTA
agarose (Qiagen); the beads were used for pull-down
assays as described earlier in the text.
Electrophoretic mobility shift assay
Nuclear extracts were prepared by washing cells in phos-
phate buffered saline (PBS), followed by re-suspension in
buffer A [10 mM of HEPES pH 7.9, 1.5mM of MgCl2,
10mM of KCl, 0.5mM of DTT, 0.5mM of PMSF and
protease inhibitor cocktail (Boehringer Mannheim)].
Nuclei were isolated by lysing cells in buffer A containing
0.1% (v/v) of NP40 on ice for 5min and centrifugation at
5800g for 30 s.
Nuclei were then lysed in buffer B (20mM of HEPES
pH 7.9, 1.5mM of MgCl2, 420mM of NaCl, 0.2mM of
EDTA, 25% of glycerol (v/v), 1mM of DTT, 0.5mM of
PMSF and 1 protease inhibitor cocktail) at 4C for
15min. Cell debris were removed by centrifugation at
11 600g for 10min at 4C, and the protein concentration
was determined (Bio-Rad). Aliquots of extract were stored
at 70C. Oligonucleotides were designed against the
human myeloperoxidase (MPO) promoter containing a
RUNX binding site. MPOF: CTGATCACTAACCACA
ACCAGTTCTGC and MPOR: CGTCTTGACCAACA
CCAA TCACTAGTC were annealed and end labelled
with [a32-P] dGTP using Klenow DNA polymerase.
EMSA reactions were carried out in a 14 ml containing
10mg of nuclear extract, 20mM of HEPES pH 7.9,
0.1M of KCl, 0.2mM of EDTA, 20% of glycerol (v/v),
0.5mM of PMSF, 10.5mM of DTT, protease inhibitor
cocktail, 5 mg of bovine serum albumin and 2 mg of poly
(dI-dC) (Sigma) and pre-incubated with cold competitor
oligonucleotides or antibodies at 25C for 5min if
required. In total, 250 000 counts (100 ng) of
32P-labelled probe was added, and the reaction mixture
was incubated at 25C for 30min. Complexes were
separated on a non-denaturing 4% of poly-acrylamide
gel in 0.5 TBE that was then ﬁxed in 10% of acetic
acid, 45% of ethanol (v/v), dried and analysed on a
phosphorimager.
Confocal microscopy
Confocal microscopy HEK293 cells were cultured on
poly-L-lysine-coated coverslips in six-well dishes at
50% density and were transfected with 3 mg of plasmid
DNA. LCLs were overlaid on to poly-L-lysine-coated
coverslips and were allowed to partially air dry before
ﬁxation. Cells were ﬁxed using 4% of paraformaldehyde
and permeabilized with 0.05% of Triton X-100 in PBS.
Primary anti-RUNX1 antibody (Oncogene) was diluted
1/500 in blocking buffer (PBS with 5% bovine serum
albumin, 0.05% of Triton X-100), and samples were
incubated overnight at 4C with shaking. The coverslips
were washed three times with blocking buffer and ﬂuores-
cein isothiocyanate-conjugated anti-rabbit secondary
antibody (Sigma) was applied at a 1/1000 dilution in
blocking buffer. The samples were again washed in
triplicate, coverslips were mounted in MOWIOL and
visualized using a confocal microscope.
Electroporation of LCLs for transient and stable
expression
The 2 106 exponentially growing IB4 LCLs were
electroporated with 5 mg of plasmid DNA using the
Neon electroporation system (Invitrogen). Cells were re-
covered in conditioned medium into 6-well plates, and
300 mg/ml of hygromycin selection was administered on
the following day. Medium containing hygromycin was
replaced every 3 or 4 days until stable outgrowth was
obtained. Cultures were tested for inducible protein ex-
pression using 1 mM of cadmium chloride (CdCl2;
Sigma). Transient cells were harvested after 2 weeks selec-
tion for analysis.
Cell-penetrating peptides
Peptides containing the N-terminus of RUNX1c residues
1–32 followed by 9 arginine residues (R1NTCPP:
MASDSIFESFPSYPQCFMRECILGMNPSRDVH RR
RRRRRRR), the D4A mutation and a scrambled
version of this sequence (CtrlCPP: MGLEDSSFFRQSY
AVEIPISMDRMSPCFCNPH RRRRRRRRR) were
obtained from Peptide Synthetics, UK. Peptides were
dissolved in DMSO at 5mM.
RESULTS
RUNX1c but not RUNX1b represses growth of LCLs
Comparison of RUNX1c protein sequences from different
species demonstrates the conservation of the N-terminal
33 amino acids that are unique to RUNX1c (Figure 1A).
The mouse and hamster Runx1c N-terminus lacks amino
acids E20–H32 present in RUNX1c of most mammals.
These amino acids are encoded by exon 2 of human
RUNX1c. Although sequence similar to exon 2 is
present in the mouse genome at an orthologous position
in the RUNX1 gene (Figure 1B), a point change in the
splice acceptor changes its essential AG to GG, most
likely preventing inclusion of this exon in the mouse
RUNX1c mRNA. The absence of this exon in the
mRNA has been noted before (13,21).
We showed previously that resting human B cells
contain RUNX1c (17). Induction of B cell proliferation
by Epstein–Barr virus infection involves induction of
RUNX3, which represses the expression of the RUNX1c
and allows the cell proliferation. We showed that expres-
sion of RUNX1c from an artiﬁcial promoter by electro-
poration of an expression plasmid causes a profound
decrease in the outgrowth of these cells, indicating that
its removal by RUNX3 has a vital role in the proliferation
or survival of activated B cells (17). Remarkably, we have
now found that RUNX1b does not prevent B cell growth
in this system (Figure 1C), providing a new assay for func-
tional difference between RUNX1c and RUNX1b in
human lymphoblastoid cells.
The ability of RUNX1c to repress LCL growth required
sequences unique to both the N- and C-terminus of
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RUNX1c because chimera R1–R3, which has the
N-terminus of RUNX1c but the C terminus of RUNX3,
failed to inhibit LCL growth (Figure 1C and D).
Expression of the RUNX proteins was checked by transi-
ent transfection into 293T cells, which do not express
RUNX1 or RUNX3. The predicted proteins were
observed in western blotting, and all were shown to be nu-
clear in an immunoﬂuorescence assay (Figure 1E and F).
The role of the N-terminal part of RUNX1c in growth
inhibition was tested directly by sequentially deleting the
RUNX1c N-terminus, creating three deletion mutants C1,
C2 and C3 (Figure 2A). These were expressed in IB4 LCLs
in the same electroporation and hygromycin selection
assay. Removal of even the ﬁrst six amino acids (C1)
was sufﬁcient to prevent the growth repressive activity of
RUNX1c (Figure 2B). The deletion mutants localized in
293T and IB4 cells similarly to RUNX1c and were ex-
pressed at similar levels (Figure 2C). These data show
that deletion of even a small section of the RUNX1c
N-terminus disrupts the growth repression function.
The RUNX1c growth repressive activity can be linked to
speciﬁc residues within the N-terminus
Our experiments so far on RUNX1c growth inhibition
were performed using a transient electroporation LCL
outgrowth assay. The small scale of this technique and
substantial cell death of untransfected cells in the
hygromycin selection hinder further analysis. We, there-
fore, developed a conditional system in which stably
transfected lymphoblastoid cell lines could be induced to
express RUNX1 alleles. RUNX1c and RUNX1b were
cloned under the control of a metallothionein-regulated
promoter using the pMEP4 plasmid. A C-terminal
TAP-tag motif was added to the RUNX1c and
RUNX1b sequences for these experiments.
This system was found to accurately demonstrate
the differential effect of RUNX1c and RUNX1b on cell
growth. Cadmium chloride (CdCl2) induction of RUNX1c
caused a decrease in the proliferation of IB4 cells, but in-
duction of RUNX1b did not have this effect (Figure 3A).
We examined the DNA content of cells over the duration
of this time course, and although RUNX1c did not seem
to have a signiﬁcant effect on any particular stage of the
cell cycle, there was a signiﬁcant increase in the sub G1
peak at 5 days induction, implying cell death was present
at later stages (Figure 3B). There was, however, no signiﬁ-
cant increase in PARP cleavage on induction of RUNX1c
(data not shown). Growth inhibition by RUNX1c thus
seems to be complex and affects multiple stages of the
cell cycle. The expression level of RUNX1c induced by
CdCl2 in the LCLs was similar to that observed in the
latency I BL cell line DG75 and so can be considered to
be physiologically normal (Figure 3C).
To determine which residues are required for the growth
repressive activity of RUNX1c, alanine scanning mutants
of all the RUNX1c N-terminal residues from S3 to H32
were prepared by site-directed mutagenesis. Stably trans-
fected IB4 cell lines of all 30 mutants were tested in a
growth assay with or without 5 days of treatment with
CdCl2. RUNX1c mutants were expressed at comparable
levels and could be divided into three categories
(Figure 4A). The ﬁrst category was residues whose muta-
tions had little or no effect on RUNX1c growth repression
and were, therefore, not required for its activity (S3, I6,
F10, Y13, P14, Q15, C16, M18, R19, M25, R29 and D30). The
second category of mutants was partially required for
RUNX1c activity (S5, E8, S9, P11, S12). The third
category was residues whose mutation abolished the
activity of RUNX1c, and, therefore, are required (D4,
F7, F17, E20, C21, I22, L23, G24, N26, P27, S28, V31, H32).
Some of these point mutants were also tested in the tran-
sient assay (without the TAP-tag). The mutants selected
behaved in a similar fashion to their stable inducible,
TAP-tagged equivalents with approximately equivalent
levels of expression (Figure 4B). Although there was
some variation in expression level, this was not related
to the ability to inhibit cell growth in these assays.
The TAP-tag in the inducible IB4 cell lines also allowed
testing for possible novel stable protein interactions de-
pendent on the N-terminus of RUNX1c. The inducible
RUNX1c and RUNX1b TAP-tagged lines were
compared in large-scale pull-down experiments, analysing
the pull-down material by mass spectrometry. Although
the association of endogenous CBF-b with both RUNX1
isoforms was conﬁrmed, we did not detect any proteins
that reproducibly interacted differentially with RUNX1c
compared with RUNX1b (data not shown). This
approach would have only detected a stable interaction
of proteins off DNA in free solution, but the result
suggests that a more subtle effect of the N-terminus on
A
B C
Figure 2. Disruption of RUNX1c N-terminus removes growth repres-
sive activity. (A) Alignment of RUNX1c with truncation mutants.
(B) The 2 106 IB4 LCLs were electroporated with pCEP4–
RUNX1c, RUNX1b and truncations C1–3. Cells were selected with
hygromycin and counted after 2 weeks selection. The results are
shown as average cell number with standard deviation as error bars,
as in Figure 1. (C) Expression of RUNX1 constructs was tested by
immunoblotting lysates using a RUNX1 antibody. b-Actin served as
a loading control. Confocal microscopy demonstrated that all three
RUNX1c truncations C1–3 localize in the nucleus similarly to
wild-type RUNX1c.
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RUNX1 function is a more likely explanation for the dif-
ferential activity.
Human–mouse differences, DNA binding and the
VWRPY motif
Reverse transcription (RT)–PCR of RNA from mouse
spleen or thymus using primers spanning exon 1 to exon
4 conﬁrmed that mice express only the recognized
RUNX1c RNA form lacking exon 2 and encoding
E20–H32 protein (data not shown). A stable IB4 indu-
cible cell line expressing a TAP-tagged human RUNX1c
splice variant lacking exon 2 (N-terminus equivalent to
mouse RUNX1c) was produced (Figure 5A) and tested
in the growth assay. As predicted from the point muta-
genesis, the E20–H32 exon 2 deletion mutant did not
inhibit LCL growth (Figure 5B) despite a similar level of
expression to the full-length RUNX1c (Figure 5C). In
mouse B cells, there is no equivalent of the EBV-infected
human B lymphoblastoid line to allow homologous testing
of mouse RUNX1c (lacking exon 2), but it seems likely
from these data that there is a difference in the function of
RUNX1c between human and mouse B cells.
A DNA binding mutant (DBM) of RUNX1c was
prepared by mutating R161 to a Glycine, a natural
mutation known to disrupt DNA binding of RUNX1b
(22). In the transient outgrowth assay in IB4 cells, the
DBM failed to repress growth, although it showed
correct sub-cellular localization in 293T and IB4 cells
(Figure 6A).
Earlier experiments (Figure 1C) had shown a require-
ment for the C-terminus of RUNX1c for growth repres-
sion that could not be provided by the C-terminus of
RUNX3. We further examined the requirement for
regions C-terminal of the RHD by generating CdCl2-in-
ducible cell lines expressing a truncated form of RUNX1c
containing sequences from the start of the protein to the
end of the RHD (RUNX1cNT), the equivalent form of
RUNX1b (RUNX1bNT) and a form lacking either the 1c
or 1b N-terminus (RUNX1NT). These cell lines inducibly
expressed high levels of RUNX1 product (Figure 6B, right
panel). Interestingly, all three proteins displayed strong
nuclear localization, although signiﬁcant, diffuse cytoplas-
mic localization was also evident (Figure 6B). These
truncated RUNX proteins lack the known C-terminal
nuclear localization motif of RUNX1 (23), but they do
contain the minimal DNA-binding domain, which may
result in diffuse localization with partial nuclear tropism
as we observe. RUNX1cNT and the other mutant forms
failed to repress LCL growth (Figure 6B, left panel),
indicating that sequences C-terminal of the RHD are
required for the growth inhibition.
The extreme C-terminus contains the VWRPY sequence,
through which TLE family transcriptional repressors are
recruited (24,25). The VWRPY deletion mutant
(RUNX1cVWRPY) repressed the growth of the IB4
cells to a similar extent as RUNX1c (Figure 6C), indicating
that it is not required for the growth repressive activity of
RUNX1c in this context. It, therefore, seems that, in
addition to the N-terminus and the DNA-binding




Figure 3. Inducible stable RUNX1c TAP-tagged IB4 cell line reconsti-
tutes growth inhibitory activity (A). Inducible IB4 pMEP4 stable cell
lines expressing RUNX1cTT and RUNX1bTT were seeded at 1 105
per ml in six-well dishes induced with 1 mM of CdCl2 and were counted
over 5 days of culture. The results presented show the average cell
number from 4–6 determinations with standard deviation as error
bars. Expression from RUNX1 constructs was tested by immunoblot-
ting lysates using a RUNX1 antibody. GAPDH was used as a loading
control. (B) Cells were harvested at day 5 post-induction, ﬁxed in 70%
(v/v) of ethanol and stained with 50 mg/ml of propidium iodide (Sigma)
containing ribonuclease A (Sigma). DNA content was then examined
by ﬂow cytometry. Percentage sub-diploid DNA content is shown.
(C) Comparison of RUNX1c proteins levels in lysates from DG75
cells and IB4 pMEP4–RUNX1cTT induced with 1 mM of CdCl2 after
immunoblotting and probing with an anti-RUNX1 monoclonal
antibody (A-2). b-Actin was the loading control.
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AB
Figure 4. RUNX1c growth inhibitory activity requires speciﬁc residues within the unique N-terminus. (A) IB4 cell lines containing pMEP–
RUNX1cTT with the indicated N-terminal mutations were seeded at 1 105 per ml in six-well dishes, induced with 1mM of CdCl2 and counted
after 5 days culture. Mutations converted the indicated original amino acid to alanine. The results are presented as average percentage growth of
induced cells compared with non-induced cells from triplicate samples with standard deviation from 4–6 determinations for each cell line. Cells with
and without 1 mM of CdCl2 were lysed in sample buffer after 5 days and immunoblotted for RUNX1c expression (shown below) with a b-actin
loading control. (B) Transient electroporation of 2 106 IB4 cells with 5 mg of pCEP–RUNX1c and selected site-directed mutants. Cells were selected
with hygromycin and counted after 2 weeks outgrowth. The results presented show the average cell number and standard deviation as error bar,
determined as earlier in the text. Cells were lysed in sample buffer after 2 weeks and immunoblotted for RUNX1c expression, using b-actin as a
loading control. Data are representative of at least three separate experiments.
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unique to RUNX1 (but not the VWRPY sequence) are
required for the ability to inhibit B cell proliferation.
As the DBM mutant of RUNX1 (Figure 6A) that
cannot bind DNA did not inhibit B cell growth, it is
likely that growth inhibition is mediated through speciﬁc
gene regulation by RUNX1. At present, we do not know
the key genes involved in this. There does not seem to be a
general difference in gene regulation because testing a
known RUNX1 target gene BLK showed no difference
in expression levels in the B cell system in response to
expression of RUNX1c or RUNX1b (Figure 6D). To
test whether there is a simple difference in the ability to
bind speciﬁcally to DNA, RUNX1c and RUNX1b were
tested in an electrophoretic mobility shift assay (EMSA)
using the known RUNX1-binding site in the MPO gene
(Figure 1E). LCL extracts could not be used for this ex-
periment because of the large amount of endogenous
RUNX3; therefore, RUNX1c or RUNX1b were
expressed by transfection in 293 cells, which contain
endogenous CBF-b but no RUNX1 or RUNX3.
Nuclear extracts were prepared and shown to have equal
amounts of RUNX1 protein (Figure 6E, lower panel). The
EMSA (Figure 6E, upper panel) showed a speciﬁc
RUNX1 complex (arrowed), which was competed by an
excess of the same non-radioactive DNA sequence but not
by a non-speciﬁc competitor. There was no signiﬁcant dif-
ference between RUNX1c and RUNX1b in the amount of
complex formed (Figure 6E). This was not a consequence
of the assay being saturated, as twice as much nuclear
extract gave an increased amount of EMSA complex.
Differential effect of RUNX1 fusion oncogenes on
LCL growth
TEL–RUNX1 is unable to repress the growth of LCLs
(17), consistent with its activity as a B cell-speciﬁc
oncogene. The absence of the N-terminus of RUNX1c
in TEL–RUNX1 might thus be relevant to the ability of
this type of translocation to cause B cell tumours. To test
whether loss of growth repression was a general property
of RUNX1 fusion oncogenes in this system, TEL–
RUNX1 or RUNX1–ETO were expressed in the transient
transfection LCL outgrowth assay. TEL–RUNX1c gave a
slight, yet consistent, increase in cell numbers but
RUNX1–ETO inhibited the outgrowth as effectively as
RUNX1c (Figure 7). Although RUNX1–ETO showed
strong nuclear localization like RUNX1c, TEL–RUNX1
was predominantly localized in the cytoplasm both in
293T cells and IB4 cells, perhaps explaining its inability
to inhibit B cell growth, irrespective of any contribution
from the absence of the N-terminal sequences speciﬁc to
RUNX1c.
The inhibition of cell growth caused by RUNX1–ETO
probably occurs by a different mechanism to that of
RUNX1c because RUNX1–ETO has a RUNX1b N-
terminus. Ectopic expression of RUNX1–ETO in early
haematopoietic development gave rise to myeloid or gran-
ulocytic but not lymphocytic cells expressing RUNX1–
ETO (26–28); mutagenesis of these mice gave rise to
myeloid malignancies (29). This suggests that, not only
is its expression in B cells not tolerated, it preferentially
leads to malignancy with a myeloid speciﬁcity.
Conversely, the opposite is true for TEL–RUNX1
(30,31). It, therefore, appears that the activity of these
oncogenic forms of RUNX1 may differ from the speciﬁc
mechanism by which RUNX1c inhibits normal B cell
proliferation.
RUNX1c and RUNX1b bind CBF-b equally
Although we found no difference in DNA binding
(Figure 6E), previous research showed that RUNX1c
binds to consensus RUNX sites somewhat more strongly
than RUNX1b in gel shift assays (13). An analogous dif-
ference in distal and proximal form binding was
demonstrated for RUNX2 (32). Both these studies used
murine RUNX1c lacking the E20–H32 region required for
growth modulating activity in human B cells; therefore,
this in vitro differential binding activity does not explain
our observations on cell growth. The DNA binding
afﬁnity of the RUNX family is modulated through the




Figure 5. Human RUNX1c lacking residues E20–H32 missing from
murine RUNX1c does not inhibit cell growth. (A) Protein sequence
alignment of RUNX1c and RUNX1c E20–H32 murine-like
N-terminal splice form (RUNX1cSP). (B) Inducible IB4 pMEP4
stable cell lines expressing TT vector alone, RUNX1cTT,
RUNX1bTT and RUNX1cSP were seeded at 1 105 per ml in
six-well dishes induced with 1mM of CdCl2 and counted after 5 days
culture. The results are presented as average percentage growth of
induced cells compared with non-induced cells from six determinations
with standard deviation shown as error bars. Cells were then lysed in
sample buffer and immunoblotted for detection of RUNX1 levels with
a GAPDH loading control. Data are representative of three separate
experiments.




Figure 6. RUNX1c proliferation block requires DNA binding and the transactivation domain but is VWRPY independent. (A) The 2 106 IB4 cells
were electroporated with 5 mg of pCEP4–RUNX1c or the RUNX1c DBM, then selected with hygromycin and counted after 2 weeks selection. The
results presented show the average cell number from six deteminations with standard deviations shown as error bars. Cells were then lysed in sample
buffer and immunoblotted for detection of RUNX1 levels and for b-actin as a loading control. Localization of the RUNX1c DBM protein by
confocal microscopy demonstrated its targeting to the nucleus as wild-type RUNX1c. (B) IB4 pMEP4 stable cell lines inducibly expressing TT vector
alone, RUNX1cTT, RUNX1bTT and truncated forms of RUNX1 were seeded at 1 105 per ml in six-well dishes, induced with 1 mM of CdCl2 and
counted after 5 days culture. The truncated forms of RUNX1 comprised the N terminal portion of each isoform to the end of the RHD
(RUNX1cNT and RUNX1bNT). RUNX1NT lacked either N-terminus, starting from sequence DAST. The results are presented as average per-
centage growth of induced cells compared with non-induced cells from six determinations with standard deviation shown as error bars. A portion of
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binding by 3-fold (33–35). We, therefore, examined the
relative ability of the RUNX1 isoforms to bind CBF-b.
CBF-b cDNA was cloned by RT-PCR from LCL cDNA
and was engineered to have either a FLAG tag or a His
tag on the C-terminus. The CBF-b–His was expressed in
E. coli and afﬁnity puriﬁed on Nickel resin beads. The
ability of this CBF-b–His to associate with RUNX1c
and RUNX1b was tested using a pull down assay with
extracts either from transfected 293T cells (Figure 8A)
or from the inducible IB4 LCLs (Figure 8B). No differ-
ence was observed between the ability of RUNX1c and
RUNX1b to associate with CBF-b.
Additionally, the CBF-b–FLAG expression plasmid
was co-transfected with RUNX1c or RUNX1b expression
plasmids into 293T cells, and immunoprecipitation was
performed with anti-FLAG antibody. Co-transfection of
RUNX1b with CBF-b caused an overall decrease in the
levels of both proteins (Figure 8C and D) but RUNX1c
did not show this effect with CBF-b. No such reduction in
the level of RUNX1b was observed when it was
co-expressed with a control protein, the EBV BZLF1 tran-
scription factor, in the same vector (Figure 8D). These
data indicate that CBF-b and RUNX1b have a speciﬁc
ability to mutually destabilize each other when acutely
expressed in 293 cells. It is difﬁcult to dismiss this as an
over-expression phenomenon because of the speciﬁcity of
the effect to the RUNX1b–CBF-b combination. However,
when we examined the levels of CBF-b in the inducible
IB4 LCLs with and without induction of RUNX1c or
RUNX1b, no such destabilization was observed
(Figure 8E). Differential CBF-b binding or destabiliza-
tion, therefore, does not seem to be an explanation for
the differences in RUNX1c and RUNX1b activity on
cell growth observed in the LCLs.
A cell permeable peptide containing the RUNX1c
N-terminus prevents the RUNX1c growth inhibition
The ability of cell permeable peptides (CPPs) to pass the
membrane and be bio-available inside cells is provided by
the nine arginine residues added to the C-terminus (36,37).
Comparing a RUNX1c N-terminal CPP and a control
scrambled sequence CPP (Figure 9A), we found that the
RUNX1c CPP speciﬁcally prevented the ability of
RUNX1c to inhibit cell growth (Figure 9B) while not af-
fecting the levels of the inducible RUNX protein in these
cells. The ability of the RUNX1c CPP to prevent cell
growth inhibition by RUNX1c was also abolished by
introducing the D4A point mutation into the peptide
(Figure 9C), corresponding to the mutagenesis shown
earlier. For this experiment, the peptides were re-
synthesized and were tested several times to conﬁrm the
ability to speciﬁcally prevent RUNX1c from inhibiting
LCL cell growth. This peptide competition might in prin-
ciple be used to manipulate RUNX1c function in
lymphoblastoid cells in vivo.
DISCUSSION
Although they only differ by the N-terminal 33 amino
acids, we show here a clear difference in the regulation of
cell growth and survival between RUNX1c and RUNX1b
in human B cells. RUNX1c is the main form found in the
lymphoid compartment, whereas RUNX1b is chieﬂy ex-
pressed in myeloid lineages (13). RUNX1c in human
resting B cells is repressed when RUNX3p44 expression
Figure 7. The RUNX1 oncogenic fusions TEL–RUNX1 and RUNX1–
ETO also exhibit differential effects on B cell proliferation. The 2 106
IB4 LCLs were electroporated with 5mg of pCEP4–RUNX1c, pCEP4–
TEL–RUNX1 or pCEP4–RUNX1–ETO, then selected with
hygromycin and counted after 2 weeks selection. The results presented
show the average cell number as aforementioned with standard devi-
ations shown as error bars. Cells were then lysed in sample buffer and
immunoblotted for detection of RUNX1 protein levels, using b-actin as
a loading control. Immunoﬂuorescence microscopy of the RUNX1c
proteins was performed to determine their localization in HEK293T
cells and LCLs. Data are representative of three separate experiments.
Figure 6. Continued
the cells was then lysed in sample buffer and immunoblotted for detection of RUNX1 levels, also using b-actin as a loading control. Some of the cells
were also used for localization of truncated RUNX1 forms by confocal microscopy. (C) IB4 pMEP4 stable cell lines expressing Tap tag vector TT
alone, RUNX1cTT, RUNX1bTT and RUNX1cVWRPY were seeded at 1 105 per ml in six well dishes, induced with 1 mM of CdCl2 and counted
after 5 days culture. The results are presented as average percentage growth of induced cells compared with non-induced cells as aforementioned.
Cells were then lysed in sample buffer and immunoblotted for detection of RUNX1 levels with a b-actin loading control. The localization of RUNX1
forms was determined by confocal microscopy. Data are representative of three separate experiments. (D) IB4 stable pMEP–RUNX1cTT and
RUNX1bTT cells were seeded at 1 105 cells per ml in six-well dishes and induced with 1 mM of CdCl2. RNA was extracted after 5 days
culture, cDNA was generated and RT–PCR was performed on samples for the expression of BLK and GAPDH. (E) The 10-cm dishes of 293T
cells were transfected with 8 mg of pCEP–RUNX1c or pCEP4–RUNX1b, and nuclear extracts from these were analysed by EMSA for binding of
RUNX factors using a 32P-labelled MPO oligonucleotide with cold competitor and non-speciﬁc probe controls. Western blotting was also performed
on nuclear extracts to demonstrate equal loading of RUNX1 protein in EMSAs.
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occurs during B cell activation either by EBV infection or
phorbol ester treatment (15). Isoform-speciﬁc effects may
thus be a key feature of RUNX biology in human B cells,
and it will be important to be aware of which isoform is
being expressed in studies on human cells. We propose that
this phenomenon can be generalized to normal human B
cell activation and that RUNX1c may contribute to the
gene expression program that holds human B cells in a
resting state before activation.
EBNA2, the EBV latent transcription factor that drives
RUNX3 expression and, therefore, RUNX1c repression,
is a functional orthologue of NotchIC, and it mimics its
normal role in B cell activation (38,39). It would be inter-
esting to examine how general this type of isoform speciﬁc
effect is in other key steps during haematopoiesis.
Levanon et al. (40) observed a dramatic decrease in
RUNX1c mRNA in both whole lymphocyte preparations





Figure 8. RUNX1c and RUNX1b interact equally with CBF-b. (A) The 10-cm dishes of HEK293T cells were transfected with 8mg of pCEP4,
pCEP–RUNX1c or pCEP–RUNX1b. Cells were lysed the following day and used for CBF-b–His protein pull-downs. A small sample of each lysate
was immunoblotted for the input level of RUNX1, using GAPDH as a loading control. CBF-b–His levels on the nickel beads were assessed by
staining the gel with Coomassie blue. Pull-down material was immunoblotted and probed for RUNX1. (B) CBF-b–His pull-downs in extracts from
IB4 stable pMEP4–RUNX1cTT and RUNX1bTT induced with CdCl2 showing pulled down material and lysate input probed for RUNX1 expres-
sion. (C) HEK293T cells were transfected with pBKCMV–CBF-b-ﬂag alone or with pCEP–RUNX1c or pCEP–RUNX1b. Cells were lysed the
following day. Anti-ﬂag pull-downs were performed, and the material was immunoblotted and probed for RUNX1 and CBF-b-ﬂag. (D) HEK293T
cells were transfected with indicated plasmids, lysed the following day and immunoblotted for RUNX1 (blot re-probed with a BZLF1 antibody),
FLAG and GAPDH. (E) IB4 pMEP4 stable cell lines expressing TT alone, RUNX1cTT or RUNX1bTT induced with 1 mM of CdCl2 for 24 h.
Extracts were immunoblotted to determine the effect on endogenous CBF-b levels. Data are representative of three separate experiments.
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A treatment, suggesting that this switch might also play a
role in T cell activation. Other work demonstrated that
overexpression of the distal but not the proximal
form severely impaired thymocyte differentiation and
suggested that RUNX1c must be downregulated to pass
the double-negative (DN) to double-positive (DP) transi-
tion (41).
Much of the published work to date characterizing the
role of RUNX1 in haematopoiesis has been conducted in
mice. Some of the residues required for RUNX1c repres-
sion of LCLs reside within the exon that is absent in
murine RUNX1c, resulting in absence of the critical
E20–H32 region from mouse RUNX1c. Although human
B cells do contain some spliced RNA corresponding to a
murine-like form of RUNX1c N terminus (data not
shown), we were unable to detect that form at the
protein level. Overall, this suggests that there may be dif-
ferences between mouse and human in this aspect of
RUNX biology and implies that not all the mouse
Runx1 data may be directly translated to the human
context.
The RUNX1 fusion oncogenes TEL–RUNX1 and
RUNX1–ETO were found to have different effects on
cell growth in our human B cell system. TEL–RUNX1
did not inhibit LCL growth but RUNX1–ETO caused a
strong inhibition of LCL growth. It is attractive to think
that the absence of the N-terminal inhibitory domain from
TEL–RUNX1 might contribute to its failure to inhibit B
cell growth, but its cytoplasmic localization coupled with
known gain-of-function contributions of the fused TEL
domain in B cells are also well established determinants
of its oncogenic nature. As RUNX1–ETO has a RUNX1b
N-terminus, it is likely that the intolerance of LCLs for
this fusion has more to do with its known adaptation to
myeloid lineages than to similarities to the growth inhibi-
tory RUNX1c activity we have described in this article.
Our deletion and mutation analysis of the N-terminal
part of RUNX1c clearly shows which N-terminal amino
acids are required for inhibition of B cell growth, but the
detailed mechanism has not yet been identiﬁed. In
addition to the N-terminus and the DNA-binding
domain, RUNX1 sequences C-terminal of the RHD and
unique to RUNX1 (but not the VWRPY) were also found
to be required for the ability to inhibit B cell proliferation.
In contrast to previous results using in vitro translated
mouse RUNX1 (amino acids 1–190) on a murine MPO
probe (13), we did not ﬁnd any signiﬁcant difference in
speciﬁc DNA binding between RUNX1c and RUNX1b.
No informative protein sequence motifs in the N-terminus
of RUNX1c could be found by computer searching, and
stably interacting proteins were not detected in mass spec-
trometry analysis comparing RUNX1c and RUNX1b. It
is likely that the N-terminus of RUNX1c forms an import-
ant contact with another protein, nucleic acid or part of
RUNX1c because of the ability of the RUNX1c
N-terminal cell permeabilizing peptide (CPP) to block its
activity. The CPP may act as a decoy to prevent associ-
ation at the novel interaction interface. An alternative ex-
planation could be that the CPP, at a higher concentration
than intracellular RUNX1c, soaks up a post-translational




Figure 9. RUNX1c N-terminal cell-permeable peptide reverses growth
repression. (A) Control scrambled and wild-type N-terminal RUNX1c
CPP peptides. (B) Three separate clones of IB4 pMEP4–RUNX1cTT
and RUNX1bTT were seeded at 1 105 cells per ml in six-well dishes,
induced with 1 mM of CdCl2 and counted after 5 days culture in the
presence of DMSO, control CPP (CtrlCPP) or RUNX1c CPP
(R1NTCPP). Each clone was counted three times, and the results are
presented as average percentage growth of induced cells compared with
non-induced cells with standard deviations shown as error bars. One
clone of each cell line type was lysed and immunoblotted to determine
the effect of CPPs on RUNX1 levels using GAPDH as a loading
control. (C) The same experiment as in part B was performed using
resynthesized peptides and including a RUNX1c D4A site mutant
(D4CPP). Data are representative of three separate experiments.
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inhibitory effect. Whatever the explanation for its activity,
this CPP represents an important novel reagent for specif-
ically blocking RUNX1c activity and may also eventually
provide a means to identify the molecular mechanism of
the speciﬁc growth inhibitory effect of RUNX1c in human
B cells. Furthermore, the behaviour of P1 RUNX1 alleles
as dominant oncogenes in retroviral insertions (42,43)
introduces the possibility of a therapeutic utility.
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